As interest in these compounds grows, many people are also seeking effective ways to anabolic steroids kaufen to maximize ...

OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.

Privately-held drugmaker Paratek Pharmaceuticals is to buy specialty pharma Optinose, including its approved product Xhance ...

Formosa Pharmaceuticals and Cipla Limited have entered into an exclusive licensing agreement for the commercialization of ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ~10‑million‑patient marketAcquisition advances Paratek’s ...

Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals to market clobetasol ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

Drug maker Cipla on Tuesday said it has inked an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for the commercialisation of clobetasol propionate ophthalmic suspension. As ...

This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits, the company stated.

Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain ...

A new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty ...